# VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

> **NCT06253364** · — · COMPLETED · sponsor: **Chen Xiaoping** · enrollment: 462 (actual)

## Conditions studied

- HCC
- Recurrence

## Interventions

- **DRUG:** PD-1 monoclonal antibody and lenvatinib

## Key facts

- **NCT ID:** NCT06253364
- **Lead sponsor:** Chen Xiaoping
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-01-31
- **Target enrollment:** 462 (ACTUAL)
- **Last updated:** 2024-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06253364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06253364, "VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06253364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*